Abstract
Background: Patients with ischemic stroke under 12 hours are typically treated with antiplatelet therapy. Combining two antiplatelet medicines agents with differing actions and antithrombotic efficacy increases the risk of hemorrhage. Among 1000 patients with ischemic stroke, dual-antiplatelet therapy was associated with 1 to 7 more ICH events than clopidogrel monotherapy and seemed to provide no significant additional benefit in reducing ischemic stroke events. Method: Search in PubMed, EMBASE, and the Cochrane Central Register about dual antiplatelet therapy versus monotherapy. The research method used was PRISMA guidelines followed by literature exclusions. The inclusion criteria in this literature search were medicinal, literature from 2013-2023. Results: There is 5 literatures discussing the advantages of DAPT with the results obtained DAPT was not associated with a significant reduction in recurrent ischemic stroke [pooled RR 0.79 (95%CI 0.67-0.92)] but was associated with a higher risk of major bleeding [pooled RR 1.86 (95%IC 1.86-3.32)]. Conclusion: Immediate administration of DAPT <12 hours after ischemic stroke can reduce recurrent stroke compared with antiplatelet monotherapy despite the increased risk of hemorrhage.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
